Selected research
Industry Research
Cancer Supportive Care Medicine Industry Research Report 2026
Market perspective
The global Cancer Supportive Care Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cancer Supportive Care Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cancer Supportive Care Medicine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cancer Supportive Care Medicine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cancer Supportive Care Medicine include Teva Pharmaceutical Industries, Johnson &Johnson, Novartis, Merck, GlaxoSmithKline, Amgen, TESARO, Kyowa Hakko Kirin and Heron Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cancer Supportive Care Medicine market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Supportive Care Medicine Market by Company
Teva Pharmaceutical Industries
Johnson &Johnson
Novartis
Merck
GlaxoSmithKline
Amgen
TESARO
Kyowa Hakko Kirin
Heron Therapeutics
Helsinn Healthcare
F. Hoffmann-La Roche
Cancer Supportive Care Medicine Segment by Type
Antiemetic Drugs
Analgesics
Granulocyte-Stimulating Agents
Erythropoietin-Stimulating Agents
Others
Cancer Supportive Care Medicine Segment by Application
Chemotherapy-Induced Anemia
Bone Metastasis
Cancer Pain
Other
Cancer Supportive Care Medicine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Supportive Care Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Supportive Care Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Supportive Care Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cancer Supportive Care Medicine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cancer Supportive Care Medicine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cancer Supportive Care Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antiemetic Drugs
- Analgesics
- Granulocyte-Stimulating Agents
- Erythropoietin-Stimulating Agents
- Others
Applications
- Chemotherapy-Induced Anemia
- Bone Metastasis
- Cancer Pain
- Other
Companies covered
- Teva Pharmaceutical Industries
- Johnson &Johnson
- Novartis
- Merck
- GlaxoSmithKline
- Amgen
- TESARO
- Kyowa Hakko Kirin
- Heron Therapeutics
- Helsinn Healthcare
- F. Hoffmann-La Roche
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cancer Supportive Care Medicine Market Size (2021-2032)
- 2.2.2 Global Cancer Supportive Care Medicine Sales (2021-2032)
- 2.2.3 Global Cancer Supportive Care Medicine Market Average Price (2021-2032)
- 2.3 Cancer Supportive Care Medicine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antiemetic Drugs
- 2.3.3 Analgesics
- 2.3.4 Granulocyte-Stimulating Agents
- 2.3.5 Erythropoietin-Stimulating Agents
- 2.3.6 Others
- 2.4 Cancer Supportive Care Medicine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Chemotherapy-Induced Anemia
- 2.4.3 Bone Metastasis
- 2.4.4 Cancer Pain
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cancer Supportive Care Medicine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cancer Supportive Care Medicine Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Cancer Supportive Care Medicine Revenue of Manufacturers (2021-2026)
- 3.4 Global Cancer Supportive Care Medicine Average Price by Manufacturers (2021-2026)
- 3.5 Global Cancer Supportive Care Medicine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cancer Supportive Care Medicine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cancer Supportive Care Medicine, Product Type & Application
- 3.8 Global Manufacturers of Cancer Supportive Care Medicine, Established Date
- 3.9 Global Cancer Supportive Care Medicine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries
- 4.1.1 Teva Pharmaceutical Industries Company Information
- 4.1.2 Teva Pharmaceutical Industries Business Overview
- 4.1.3 Teva Pharmaceutical Industries Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Cancer Supportive Care Medicine Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Recent Developments
- 4.2 Johnson &Johnson
- 4.2.1 Johnson &Johnson Company Information
- 4.2.2 Johnson &Johnson Business Overview
- 4.2.3 Johnson &Johnson Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson &Johnson Cancer Supportive Care Medicine Product Portfolio
- 4.2.5 Johnson &Johnson Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Cancer Supportive Care Medicine Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Cancer Supportive Care Medicine Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Cancer Supportive Care Medicine Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Amgen
- 4.6.1 Amgen Company Information
- 4.6.2 Amgen Business Overview
- 4.6.3 Amgen Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Amgen Cancer Supportive Care Medicine Product Portfolio
- 4.6.5 Amgen Recent Developments
- 4.7 TESARO
- 4.7.1 TESARO Company Information
- 4.7.2 TESARO Business Overview
- 4.7.3 TESARO Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 TESARO Cancer Supportive Care Medicine Product Portfolio
- 4.7.5 TESARO Recent Developments
- 4.8 Kyowa Hakko Kirin
- 4.8.1 Kyowa Hakko Kirin Company Information
- 4.8.2 Kyowa Hakko Kirin Business Overview
- 4.8.3 Kyowa Hakko Kirin Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kyowa Hakko Kirin Cancer Supportive Care Medicine Product Portfolio
- 4.8.5 Kyowa Hakko Kirin Recent Developments
- 4.9 Heron Therapeutics
- 4.9.1 Heron Therapeutics Company Information
- 4.9.2 Heron Therapeutics Business Overview
- 4.9.3 Heron Therapeutics Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Heron Therapeutics Cancer Supportive Care Medicine Product Portfolio
- 4.9.5 Heron Therapeutics Recent Developments
- 4.10 Helsinn Healthcare
- 4.10.1 Helsinn Healthcare Company Information
- 4.10.2 Helsinn Healthcare Business Overview
- 4.10.3 Helsinn Healthcare Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Helsinn Healthcare Cancer Supportive Care Medicine Product Portfolio
- 4.10.5 Helsinn Healthcare Recent Developments
- 4.11 F. Hoffmann-La Roche
- 4.11.1 F. Hoffmann-La Roche Company Information
- 4.11.2 F. Hoffmann-La Roche Business Overview
- 4.11.3 F. Hoffmann-La Roche Cancer Supportive Care Medicine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 F. Hoffmann-La Roche Cancer Supportive Care Medicine Product Portfolio
- 4.11.5 F. Hoffmann-La Roche Recent Developments
5 Global Cancer Supportive Care Medicine Market Scenario by Region
- 5.1 Global Cancer Supportive Care Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cancer Supportive Care Medicine Sales by Region: 2021-2032
- 5.2.1 Global Cancer Supportive Care Medicine Sales by Region: 2021-2026
- 5.2.2 Global Cancer Supportive Care Medicine Sales by Region: 2027-2032
- 5.3 Global Cancer Supportive Care Medicine Revenue by Region: 2021-2032
- 5.3.1 Global Cancer Supportive Care Medicine Revenue by Region: 2021-2026
- 5.3.2 Global Cancer Supportive Care Medicine Revenue by Region: 2027-2032
- 5.4 North America Cancer Supportive Care Medicine Market Facts & Figures by Country
- 5.4.1 North America Cancer Supportive Care Medicine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cancer Supportive Care Medicine Sales by Country (2021-2032)
- 5.4.3 North America Cancer Supportive Care Medicine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cancer Supportive Care Medicine Market Facts & Figures by Country
- 5.5.1 Europe Cancer Supportive Care Medicine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cancer Supportive Care Medicine Sales by Country (2021-2032)
- 5.5.3 Europe Cancer Supportive Care Medicine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cancer Supportive Care Medicine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cancer Supportive Care Medicine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cancer Supportive Care Medicine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cancer Supportive Care Medicine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cancer Supportive Care Medicine Market Facts & Figures by Country
- 5.7.1 South America Cancer Supportive Care Medicine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cancer Supportive Care Medicine Sales by Country (2021-2032)
- 5.7.3 South America Cancer Supportive Care Medicine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Cancer Supportive Care Medicine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cancer Supportive Care Medicine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cancer Supportive Care Medicine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cancer Supportive Care Medicine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cancer Supportive Care Medicine Sales by Type (2021-2032)
- 6.1.1 Global Cancer Supportive Care Medicine Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Cancer Supportive Care Medicine Sales Market Share by Type (2021-2032)
- 6.2 Global Cancer Supportive Care Medicine Revenue by Type (2021-2032)
- 6.2.1 Global Cancer Supportive Care Medicine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cancer Supportive Care Medicine Revenue Market Share by Type (2021-2032)
- 6.3 Global Cancer Supportive Care Medicine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cancer Supportive Care Medicine Sales by Application (2021-2032)
- 7.1.1 Global Cancer Supportive Care Medicine Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Cancer Supportive Care Medicine Sales Market Share by Application (2021-2032)
- 7.2 Global Cancer Supportive Care Medicine Revenue by Application (2021-2032)
- 7.2.1 Global Cancer Supportive Care Medicine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cancer Supportive Care Medicine Revenue Market Share by Application (2021-2032)
- 7.3 Global Cancer Supportive Care Medicine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cancer Supportive Care Medicine Value Chain Analysis
- 8.1.1 Cancer Supportive Care Medicine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cancer Supportive Care Medicine Production Mode & Process
- 8.2 Cancer Supportive Care Medicine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cancer Supportive Care Medicine Distributors
- 8.2.3 Cancer Supportive Care Medicine Customers
9 Global Cancer Supportive Care Medicine Analyzing Market Dynamics
- 9.1 Cancer Supportive Care Medicine Industry Trends
- 9.2 Cancer Supportive Care Medicine Industry Drivers
- 9.3 Cancer Supportive Care Medicine Industry Opportunities and Challenges
- 9.4 Cancer Supportive Care Medicine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst